Curevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved products Seattle, WA – May 26, 2026 – Curevo Vaccine (Curevo), a clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announced entry into a definitive…Read More
“When I agreed to join Hanson Medical, I knew we faced a multitude of challenges that had to be promptly addressed. As we evaluated the capital needs and cost structure of the company, I needed a CFO who could be a balanced and trusted business partner. I needed someone to ensure my strategy was being implemented effectively, essentially an extension of me. Chris Lowe, my FLG partner, was immediately effective in guiding our financing strategy and implementing our cost reduction plans. The success of these programs allowed us to then pursue a strategic sale. Our achievements could not have been done without FLG’s support.”
